StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $61.28MP/E –Yield –

Acrivon Therapeutics cash

Cash and short-term investments held at the end of each period.

Acrivon Therapeutics's cash was $89.96M at Jun 30, 2026. For fiscal 2025 it was $118.58M, down 33.9% from the year before. The highest annual figure on record is $179.48M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$118.58M-33.9%
FY2024Dec 31, 2024$179.48M+40.8%
FY2023Dec 31, 2023$127.46M-0.2%
FY2022Dec 31, 2022$127.75M+28.3%
FY2021Dec 31, 2021$99.60M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$89.96M-34.5%
Q1 FY2026Mar 31, 2026$97.74M-34.7%
Q4 FY2025Dec 31, 2025$118.58M-33.9%
Q3 FY2025Sep 30, 2025$129.25M-31.0%
Q2 FY2025Jun 30, 2025$137.42M-23.9%
Q1 FY2025Mar 31, 2025$149.64M+36.1%
Q4 FY2024Dec 31, 2024$179.48M+40.8%
Q3 FY2024Sep 30, 2024$187.45M+31.9%
Q2 FY2024Jun 30, 2024$180.54M+19.6%
Q1 FY2024Mar 31, 2024$109.98M-8.5%
Q4 FY2023Dec 31, 2023$127.46M-0.2%
Q3 FY2023Sep 30, 2023$142.09M+85.0%
Q2 FY2023Jun 30, 2023$150.95M+80.0%
Q1 FY2023Mar 31, 2023$120.21M+32.4%
Q4 FY2022Dec 31, 2022$127.75M+28.3%
Q3 FY2022Sep 30, 2022$76.80M+2025.1%
Q2 FY2022Jun 30, 2022$83.86M–
Q1 FY2022Mar 31, 2022$90.77M–
Q4 FY2021Dec 31, 2021$99.60M–
Q3 FY2021Sep 30, 2021$3.61M–

More Acrivon Therapeutics figures

See a number that looks wrong?